Immatics N.V.
Immatics is a clinical-stage biopharmaceutical company developing T-cell receptor-based immunotherapies for people with cancer. Its pipeline focuses on PRAME, a target expressed in more than 50 cancers, and includes cell therapies and off-the-shelf bispecifics. Product candidates include anzu-cel for advanced melanoma, IMA203CD8 for other PRAME-expressing solid cancers, and IMA402, a PRAME bispecific. The company also develops product candidates beyond PRAME and conducts partnered research, including a clinical trial combining anzu-cel with Moderna’s mRNA-4203. Immatics’ therapies are investigational and are being evaluated in clinical trials. Its patient-specific cell therapies are made from patients’ own T cells and are intended as one-time infusions; its bispecifics are designed for repeat dosing and distribution through standard pharmaceutical supply channels. Immatics is headquartered in Tübingen, Germany, with its corporate seat in Amsterdam, the Netherlands, and a U.S. executive office in Stafford, Texas.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $IMTX in the last 30 days.
See all $IMTX insider activity →Immatics NV (IMTX) reported Q3 EPS of €-0.50, missing estimates by €0.05, and revenue of €6.9M, below expectations of €10.88M. The stock is down 31.89% over 3 months and 30.58% over 12 months. InvestingPro rates its financial health as 'weak performance'.
Immatics reported Q3 2026 results, highlighting progress in its SUPRAME Phase 3 trial for anzu-cel (IMA203) in advanced melanoma, with enrollment on track to complete by year-end. Topline data is expected in H1 2027, followed by a BLA submission. The company also presented updated Phase 1 data for IMA203CD8 and IMA402 at ESMO Congress 2026, showing promising anti-tumor activity. Immatics had $536.3 million in cash as of September 30, 2026, projecting runway into Q4 2028.
Immatics N.V. (IMTX) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 PRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three- and nine-month period ended September 30, 2026, included herein, have been prepared in accordance with International Accounting Standard 34 (“Interim Financial Reporting
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning IMTX (Immatics N.V.). Coverage has skewed bearish: 1 bullish, 0 neutral, and 2 bearish.
Recent IMTX coverage spans earnings, technology and financial news.
Earnings miss likely triggers sell pressure.
Positive early‑stage trial data and strong cash runway could lift the stock, while upcoming H1‑2027 topline readout adds upside potential.
Earnings miss and widening loss likely pressure the stock lower.
Positive early‑stage data may lift sentiment and attract speculative buying.
Positive early‑stage data may boost investor sentiment and drive short‑term upside.
AlphAI scores every news story that mentions IMTX with an AI model for sentiment and relevance, and aggregates insider trades from Immatics N.V.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Immatics NV (IMTX) reported Q3 EPS of €-0.50, missing estimates by €0.05, and revenue of €6.9M, below expectations of €10.88M. The stock is down 31.89% over 3 months and 30.58% over 12 months. InvestingPro rates its financial health as 'weak performance'.
Immatics reported Q3 2026 results, highlighting progress in its SUPRAME Phase 3 trial for anzu-cel (IMA203) in advanced melanoma, with enrollment on track to complete by year-end. Topline data is expected in H1 2027, followed by a BLA submission. The company also presented updated Phase 1 data for IMA203CD8 and IMA402 at ESMO Congress 2026, showing promising anti-tumor activity. Immatics had $536.3 million in cash as of September 30, 2026, projecting runway into Q4 2028.
Immatics N.V. (IMTX) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 PRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three- and nine-month period ended September 30, 2026, included herein, have been prepared in accordance with International Accounting Standard 34 (“Interim Financial Reporting
Immatics N.V. (IMTX) reported Phase 1 data for IMA402 and IMA203CD8, showing 32% cORR in PRAME-high melanoma and 41% cORR across tumors, respectively. Both treatments demonstrated manageable safety profiles. The company plans to advance development across multiple solid tumor indications, including melanoma and gynecologic cancers.
Immatics N.V. (IMTX) reported updated clinical trial data for IMA402 and IMA203CD8. IMA402 showed a 32% cORR and 91% 1-year OS in advanced melanoma patients. IMA203CD8 achieved a 55% cORR in gynecologic cancers with a median DOR of 8.4 months. Both treatments demonstrated favorable safety profiles. The data were presented at the ESMO 2026 meeting.
Immatics N.V. has a lock-up agreement ending on 24-OCT-2026, restricting officers and directors from selling shares or derivatives for 60 days. The biopharmaceutical company focuses on precision targeting of PRAME with multiple clinical-stage programs. Various composite ratings are provided for the company.
Stifel initiated coverage of Immatics with a Buy rating and $15 price target, implying 119.6% upside from the Oct 13 close. The firm cites positive clinical trial outlook and strong market positioning for anzu-cel therapy, expected to launch in early 2028.
PERCEPTIVE ADVISORS LLC purchased 863,060 indirectly-held shares of Immatics N.V. (IMTX) at $8.69 ($7.50M total) on 2026-08-26. Filed jointly with EDELMAN JOSEPH (Director) and PERCEPTIVE LIFE SCIENCES MASTER FUND LTD (Director).
Immatics (IMTX) raised $161.1 million via an equity offering, including 15.5 million shares and pre-funded warrants. Proceeds will fund R&D, manufacturing, and potential commercialization of its oncology pipeline, as well as general corporate purposes.
Tenax Therapeutics (TENX) rose 27.8% premarket despite a Phase 3 trial setback, planning to discuss revised development plans with the FDA. TherapeuticsMD (TXMD) reported Q2 revenue decline but expects a milestone payment. Kura Oncology (KURA) gained 10.38% on strong Komzifti adoption. Anavex Life Sciences (AVXL) returned to profit in Q3 2026, advancing blarcamesine. Immatics (IMTX) rose 6.78% after a $150M offering. RenovoRx (RNXT) gained 16.40% on positive pancreatic cancer data.
